MenACWY-TT与Tdap及AS04-HPV16/18在女孩和年轻女性中联合接种具有免疫原性:一项III期随机试验结果
这项III期随机试验将1300名9-25岁健康女性按1:1:1:1:1随机分组,评估MenACWY-TT、AS04-HPV16/18和Tdap联合接种的免疫原性、安全性和反应原性。结果显示联合接种对MenACWY-TT和AS04-HPV16/18的免疫原性非劣于分别接种,除百日咳抗原外所有疫苗成分联合接种均非劣于单独接种或与AS04-HPV16/18联合接种;未发现安全性问题。
要点
- MenACWY-TT与AS04-HPV16/18联合接种的免疫原性非劣于两种疫苗分别接种。
- 除百日咳抗原外,MenACWY-TT、AS04-HPV16/18和Tdap联合接种对所有疫苗成分的免疫原性非劣于MenACWY-TT单独接种或Tdap与AS04-HPV16/18联合接种。
- 接种后≥89.5%的参与者对所有抗原达到预先指定阈值以上的抗体水平,未发现安全性问题。
核心结论
- 数据支持在青少年中联合接种MenACWY-TT与Tdap及AS04-HPV16/18疫苗。
研究设计与样本
- IIIb期研究(NCT01755689),1300名9-25岁健康女性按1:1:1:1:1随机分组。
- 分组接种MenACWY-TT、AS04-HPV16/18和Tdap的不同组合,评估免疫原性、安全性和反应原性。
主要发现
- MenACWY-TT和AS04-HPV16/18联合接种时免疫原性非劣于两种疫苗分别接种。
- 除百日咳抗原外,MenACWY-TT、AS04-HPV16/18和Tdap联合接种对所有疫苗成分的免疫原性非劣于MenACWY-TT单独接种或Tdap与AS04-HPV16/18联合接种。
- 接种后≥89.5%的参与者对所有抗原达到预先指定阈值以上的抗体水平。
- 未发现安全性问题。
临床怎么用
- 作者认为数据支持在青少年中联合接种MenACWY-TT与Tdap及AS04-HPV16/18疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Co-administration of vaccines in adolescents may improve coverage. We assessed co-administration of quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT), human papillomavirus 16/18 AS04-adjuvanted vaccine (AS04-HPV16/18) and tetanus-diphtheria-acellular pertussis vaccine (Tdap) in girls and young women. METHODS: In this phase IIIb study (NCT01755689), 1300 healthy 9-25-year-old females were randomized (1:1:1:1:1) to receive: MenACWY-TT at month (M) 0 and AS04-HPV16/18 at M1, M2, M7; MenACWY-TT and AS04-HPV16/18 at M0 and AS04-HPV16/18 at M1, M6; AS04-HPV16/18 at M0, M1, M6; MenACWY-TT, Tdap and AS04-HPV16/18 at M0 and AS04-HPV16/18 at M1, M6; Tdap and AS04-HPV16/18 at M0 and AS04-HPV16/18 at M1, M6. Immunogenicity, safety and reactogenicity were evaluated. RESULTS: Immunogenicity of MenACWY-TT and AS04-HPV16/18 when co-administered was non-inferior to that of the 2 vaccines given separately. Co-administration of MenACWY-TT, AS04-HPV16/18 and Tdap was non-inferior to MenACWY-TT administered alone or to Tdap co-administered with AS04-HPV16/18 in terms of immunogenicity for all vaccine components, except pertussis antigens. Post-vaccination, ≥89.5% of participants reached antibody levels above the pre-specified threshold for all antigens. No safety concerns were identified. CONCLUSION: Our data support co-administration of MenACWY-TT with Tdap and AS04-HPV16/18 vaccines in adolescents.
引用
- Rivera L, Chanthavanich P, Põder A, et al. MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial. Vaccine. 2018. PMID: 29789243. doi:10.1016/j.vaccine.2018.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。